- Report
- March 2025
- 181 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- September 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- June 2024
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- October 2024
- 250 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2022
- 152 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Book
- April 2022
- 288 Pages
- Book
- January 2020
- 240 Pages
- Book
- December 2018
- 424 Pages
- Book
- January 2025
- 256 Pages
- Book
- December 2011
- 368 Pages
- Book
- February 2011
- 366 Pages
The Respiratory Medicine market within the context of Pulmonary Medicine is a specialized field of medicine that focuses on the diagnosis and treatment of diseases and disorders of the respiratory system. This includes conditions such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary hypertension, and sleep-disordered breathing. Respiratory Medicine also encompasses the management of airway diseases, lung cancer, and other pulmonary conditions.
The Respiratory Medicine market is composed of a variety of stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare providers, and research institutions. These stakeholders are involved in the development of new treatments, diagnostic tools, and technologies to improve the quality of care for patients with respiratory diseases.
Some of the companies in the Respiratory Medicine market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Show Less Read more
